Deciphera Pharmaceuticals concludes public offering at USD37.00 per share

US FDA agrees to PharmaMar's proposal to file for accelerated approval of New Drug Application for lurbinectedin in monotherapy

US FDA approves Celgene's Inrebic

Series of potent RET kinase inhibitors designed by Xynomic Research Institute

European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis

CTD Presents New Data Presented at Annual Gathering of Patients and Families Tackling Niemann-Pick Disease Type C

Bioasis Names Dircks as Chief Operating Officer

FDA Approves Genentech's Rozlytrek for People with ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors

Zimmer Biomet wins first FDA approval for the Tether for treating scoliosis in pediatrics

AbbVie passes US FDA approval for RINVOQ for treating moderate to severe Rheumatoid Arthritis (RA)

The United States Food and Drug Administration grants approval to AbbVie's rheumatoid arthritis drug RINVOQ

Moleculin Biotech reports Q2 2019 financial results

US FDA grants approval to Roche's Rozlytrek

Onco360 to dispense Inrebic (fedratinib) under specialty pharmacy network with Celgene

Deciphera Pharmaceuticals Prices USD 400m Stock Offering